Skip to Main Content

Key Clinical Updates in Intracranial & Spinal Mass Lesions

In patients with glioblastoma with methylated methylguanine- DNA methyltransferase (MGMT) promoter, combination therapy with lomustine and temozolomide improved median survival from 31 to 48 months in a randomized controlled trial.



  • Generalized or focal disturbance of cerebral function, or both.

  • Increased intracranial pressure in some patients.

  • Neuroradiologic evidence of space-occupying lesion.

General Considerations

Roughly one-third of all primary intracranial neoplasms (Table 24–4) are meningiomas, one-quarter are gliomas, and the remainder are pituitary adenomas (see Chapter 26), neurofibromas, and other tumors. Certain tumors, especially neurofibromas, hemangioblastomas, and retinoblastomas, may have a familial basis, and congenital factors bear on the development of craniopharyngiomas. Tumors may occur at any age, but certain gliomas show particular age predilections.

Table 24–4.Primary intracranial tumors (listed by major histology grouping and by incidence within each group).

Pop-up div Successfully Displayed

This div only appears when the trigger link is hovered over. Otherwise it is hidden from view.